壳寡糖抗痛风作用研究
|
摘要
目的
研究壳寡糖对急、慢性痛风的预防作用,探讨其作用机制,以研发防治痛风的天然新药。
方法
1.用尿酸钠晶体(MSU)溶液注入大鼠右侧踝关节腔制造急性痛风模型。大鼠随机分为正常对照组、模型组、阳性药对照组和预防组(n=8),观察壳寡糖对大鼠急性痛风性关节炎的关节周径、血白细胞数及血清IL-1B的影响。
2.用腺嘌呤和乙胺丁醇灌胃法制备大鼠高尿酸血症痛风模型。大鼠随机分为正常对照组、模型组、阳性药对照组和预防组(n=8),观察壳寡糖对大鼠慢性痛风的黄嘌呤氧化酶活性、血尿酸、尿素氮、肌酐水平及肾脏病理的影响。
结果
1.MSU可诱发大鼠急性痛风性关节炎,壳寡糖对关节肿胀有抑制作用,升高血白细胞数,降低血清IL-1β(P<0.01)。
2.腺嘌呤和乙胺丁醇灌胃法可诱导大鼠慢性痛风模型,壳寡糖可降低大鼠黄嘌呤氧化酶活性,尿酸、尿素氮和肌酐水平(P<0.01)；减少肾小管内MSU及炎细胞浸润,减轻肾小管损伤。
结论
1.壳寡糖在大鼠急性痛风性关节炎模型,可抑制急性痛风性关节炎发作。
2.壳寡糖在大鼠高尿酸血症动物模型,可预防慢性痛风。
Objective
To investigate the effect of Chitosan oligosaccharide on acute and chronic gout as well as mechanisms in order to develop new natural drug to control gout.
Methods
1. After an acute gouty arthritis model of rat was established with monosodium urate crystal (MSU), animals were randomly divided into normal control group, model group, positive control group and three prevented groups(n=8). The effect of Chitosan oligosaccharide on ankle perimeters, leucocyte count and IL-1βtest of rats was observed.
2. After a chronic gout model of rat was established with adenine and ethambutol, animals were randomly divided into normal control group, model group, positive control group and three prevented groups(n=8). The effect of Chitosan oligosaccharide on activity of XOD, level of UA, BUN and CRE as well as pathological changes of kidney was observed.
Results
1. An acute gouty arthritis model of rat could be induced by MSU. Chitosan oligochitosan exhibited inhibitive effect on swelling of ankle and increased leucocytes as well as decreasing IL-1βof model rats (P<0.01).
2. A chronic gout model of rat was established with adenine and ethambutol. Chitosan oligochitosan could lower activity of XOD and decrease level of UA, BUN and CRE (P<0.01). Monosodium urate crystals, cellular infiltration and damage of kidney tubules were reduced in Chitosan oligochitosan groups.
Conclusion
1. Chitosan oligochitosan can inhibit the attack of acute gouty arthritis in rats.
2. Chitosan oligochitosan can prevent chronic gout in the hyperuricemia model of rats.
研究壳寡糖对急、慢性痛风的预防作用,探讨其作用机制,以研发防治痛风的天然新药。
方法
1.用尿酸钠晶体(MSU)溶液注入大鼠右侧踝关节腔制造急性痛风模型。大鼠随机分为正常对照组、模型组、阳性药对照组和预防组(n=8),观察壳寡糖对大鼠急性痛风性关节炎的关节周径、血白细胞数及血清IL-1B的影响。
2.用腺嘌呤和乙胺丁醇灌胃法制备大鼠高尿酸血症痛风模型。大鼠随机分为正常对照组、模型组、阳性药对照组和预防组(n=8),观察壳寡糖对大鼠慢性痛风的黄嘌呤氧化酶活性、血尿酸、尿素氮、肌酐水平及肾脏病理的影响。
结果
1.MSU可诱发大鼠急性痛风性关节炎,壳寡糖对关节肿胀有抑制作用,升高血白细胞数,降低血清IL-1β(P<0.01)。
2.腺嘌呤和乙胺丁醇灌胃法可诱导大鼠慢性痛风模型,壳寡糖可降低大鼠黄嘌呤氧化酶活性,尿酸、尿素氮和肌酐水平(P<0.01)；减少肾小管内MSU及炎细胞浸润,减轻肾小管损伤。
结论
1.壳寡糖在大鼠急性痛风性关节炎模型,可抑制急性痛风性关节炎发作。
2.壳寡糖在大鼠高尿酸血症动物模型,可预防慢性痛风。
Objective
To investigate the effect of Chitosan oligosaccharide on acute and chronic gout as well as mechanisms in order to develop new natural drug to control gout.
Methods
1. After an acute gouty arthritis model of rat was established with monosodium urate crystal (MSU), animals were randomly divided into normal control group, model group, positive control group and three prevented groups(n=8). The effect of Chitosan oligosaccharide on ankle perimeters, leucocyte count and IL-1βtest of rats was observed.
2. After a chronic gout model of rat was established with adenine and ethambutol, animals were randomly divided into normal control group, model group, positive control group and three prevented groups(n=8). The effect of Chitosan oligosaccharide on activity of XOD, level of UA, BUN and CRE as well as pathological changes of kidney was observed.
Results
1. An acute gouty arthritis model of rat could be induced by MSU. Chitosan oligochitosan exhibited inhibitive effect on swelling of ankle and increased leucocytes as well as decreasing IL-1βof model rats (P<0.01).
2. A chronic gout model of rat was established with adenine and ethambutol. Chitosan oligochitosan could lower activity of XOD and decrease level of UA, BUN and CRE (P<0.01). Monosodium urate crystals, cellular infiltration and damage of kidney tubules were reduced in Chitosan oligochitosan groups.
Conclusion
1. Chitosan oligochitosan can inhibit the attack of acute gouty arthritis in rats.
2. Chitosan oligochitosan can prevent chronic gout in the hyperuricemia model of rats.
引文
1陆林.浅谈痛风病的药物治疗[J].医学理论与实践,2007,20(6)：651-652.
2邵继红,徐耀初,莫宝庆,等.痛风与高尿酸血症的流行病学研究进展[J].疾病控制杂志,2004,8(2)：152-154.
3李昌臣.高尿酸血症的定义及病型分类[J].医师进修杂志,1998,21(6)：281-282.
4赵文婷,姚华.高尿酸血症与相关基因关系的研究[J].泰山医学院学报,2008,29(5)：394-396.
5叶玉津,尹培达.痛风性关节炎的诊治进展[J].新医学,2002,33(9)：524-525.
6 Conaghan PG, Day RO. Risk and benefits of drugs used in the management and prevention of gout[J]. Drugs,1994,11(4):252-258.
7 Ben Chetrit E, Levy M. Colchicine:1998 update [J]. Semin Arthritis Rheum,1998,28(1): 48-59.
8陈光亮,王钦茂,徐叔云.小鼠高尿酸血症模型的研究[J].中国药理学通报,2001,17(3)：350-352.
9陈光亮,张清林,徐叔云,等.酵母致小鼠高尿酸血症模型[J].中国药理学通报,2003,19(4)：4697-4699.
10陈光亮,徐叔云.高尿酸血症动物模型研究进展[J].中国药理学通报,2004,20(4)：369-373.
11陈云凤,肩晓宇,彭介寿.痛风宁I号抗炎及镇痛作用的研究[J].中药药理与临床,2000,16(4)：38-39.
12陈文照,金策,林坚,等.痛风宁对尿酸钠致大鼠关节炎模型前列腺素的影响[J].中国医药学报,2000,15(2)：104-106.
13胡志鹏.壳寡糖的研究进展[J].中国生化药物杂志,2003,24(4)：210-212.
14 Synowiecki J, AI-Khateeb NA. Production, properties, and some new applications of chitin and its derivatives [J]. Crit Rev Food Sci Nutr,2003,43(2):145-171.
15 Romoren K, Thu BJ, Evensen 0. Immersion delivery of plasmid DNA. II. A study of the potentials of a chitosan based delivery system in rainbow trout (Oncorhynchus mykiss) fry[J]. J Control Release,2002,85(1-3):215-225.
16 Risbud M, Bhonde M, Bhonde R. Chitosan-polyvinyl pyrrolidone hydrogel does not activate macrophages potentials for transplantation applications [J]. Cell fransplant,2001,10(2):195-202.
17 Vord PJ, Matthew HW, Silva SP, et al. Evaluation of the biocompatibility of a chatosan scaffol in mice [J]. J Biomed Mater Res,2002,59(3):585-590.
18熊宇龙,匡欣薇,陈卫国,等.壳寡糖的免疫调节效应及其机制研究进展[J].现代生物医学进展,2009,9(9)：1787-1789.
19官杰,罗晓庆,王琪,等.壳寡糖抑制肿瘤作用的实验研究[J].中国免疫学杂志,2007,23(5)：421-425.
20 Zheng Wang, Lanhong Zheng, Shaoli Yang, et al. N-acetylchitooligosaceharide is a potent angiogenic inhibitor both in vivo and in vitro [J]. Biochem Biophys Res Commun, 2007,357(1):26-31.
21吴海明,华晓阳,何登全.壳寡糖抗肿瘤作用及免疫调节机理的研究[J].中华医学研究杂志,2005,5(8)：729-731.
22刘冰,刘万顺,韩宝芹,等.壳寡糖及其衍生物对实验性糖尿病大鼠调节血脂和抗氧化作用[J].山东大学学报(理学版),2006,41(4)：158-163.
23沈若武,王守彪,夏玉军.壳寡糖对新西兰兔骨折愈合的影响[J].解剖学杂志,2005,28(3)：340-342.
24王秀武,杜昱光,白雪芳,等.壳寡糖对肉仔鸡肠道主要菌群、小肠微绒毛密度、免疫功能及生产性能的影响[J].动物营养学报,2003,15(4)：32-35.
25张剑勇,杨卓欣,孙景波,等.护肾痛风泰冲剂对痛风肾大鼠型前胶原的影响[J].中医药学刊,2004,22(2)：245-246.
26王叶新.急性痛风性关节炎的治疗进展[J].中国骨质疏松杂志,2007,13(1)：74-76.
27徐叔云,卞如镰,陈修.药理实验方法学[M].第三版.北京：人民卫生出版社,2002.202-204.
28 Terkeltaub R, Baird S, Sears P, et al. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in air pouch model of acute urate crystal-induced gouty synovitis[J]. Arthritis Rheum,1998, 41(5):900-999.
29 Terkeltaub R. Pathogenesis and treatment of crystal-induced inflammation in Koopman WJ. Arthritis and allied conditions a text book rheumatology [J]. Baltimore Williams and Wilkins,1996,16(5):'2085-2806.
30方圻.现代内科学[M].北京：人民军医出版社,1995.2873-2875.
31 Coderre TJ, Wall PD. Ankle joint urate arthritis (AJUA) in rats:an alternative animal model of arthritis to that produced by Freund's adjuvant[J]. Pain,1987,28(3): 379-393.
32 Coderre TJ, Wall PD. Ankle joint arthritis in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents[J]. Pharm Biochem Behav,1988, 29(3):461-463.
33金红兰,郭瑞新.复方白虎加桂枝汤防治大鼠痛风模型的实验观察[J].深圳中西医结合杂志,2005,15(4)：199-201.
34卢笑倩.痛风急性期的药物治疗与分析[J].哈尔滨医药,2009,29(4)：46.
35 Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation:in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1[J]. Arthritis Rheum,1997, 40(5):955-965.
36刘湘源,李树强.痛风急性发作期的治疗进展[J].中华临床医师杂志,2009,3(3)：474-477.
37甘秀红.痛风病诊治的研究进展[J].右江医学,2007,35(5)：587-589.
38王大山,安利国,杨桂文.壳聚糖对巨噬细胞的双向免疫调节作用[J].生命的化学,2009,29(1)：60-63.
39 Fujiwara K, Ohkawara S, Takagi K, et al. Involvement of CXC chemokine growth-related oncogene-alpha in monosodium urate crystal-induced arthritis in rabbits[J]. Lab Invest,2002,82(10):1297-1304.
40 Matsukawa A, Yoshimura T, Maeda T, et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-lbeta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis[J]. Lab Invest,1998,78(5):559-569.
41 Choi H K, Mount D B, Reginato A M. Pathogenesis of gout[J]. Ann Intern Med,2005, 143(7):499-516.
42张超,曹克光,杨崇青,等.高尿酸血症及尿酸性肾病动物模型的建立及应用[J].实验动物科学与管理,1999,16(4)：18-21.
43苏友新,陈伟宏,王和鸣,等.高尿酸血症及痛风性关节炎的动物模型研究概况[J].中国骨伤,2004,17(7)：444-445.
44王丹,张三印,代勇,等.高尿酸血症及痛风动物模型研究概况[J].山东中医杂志,2008,27(8)：573-575.
45金沈锐,秦旭华.痛风及高尿酸血症动物模型的研究现状和评价[J].中国实验动物学报,2005,13(1)：55-58.
46熊湘明,曲竹秋.大鼠高尿酸血症模型建立[J].天津中医学院学报,2001,20(4)：28-29.
47 Anzai N, Enomoto A, Endou H. Renal urate handling clinical relevance of recent advances [J]. Curr Rheumatol Rep,2005,7(3):227-234.
48 Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport [J]. Physiology (Bethesda),2005,20(1):125-133.
49孔悦,张冰,刘小青,等.黄嘌呤氧化酶活性在高尿酸血症动物模型中的变化[J].北京中医药大学学报,2004,27(6)：38-40.
50朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8)：803-806.
51孟昭亨.痛风[M].第1版.北京：北京医科大学中国协和医科大学联合出版社,1997.285.
52 Meyers OL, Cassim B, Mody GM. Hyperuricemia and gout:clinical guideline 2003[J]. S Afr Med J,2003,93(12):961-971.
53刘波.痛风的病理[J].中国社区医师,2002,16(7)：13-14.
1李昌臣.高尿酸血症的定义及病型分类[J].医师进修杂志,1998,21(6)：281-282.
2林伟青,谢建祥.高尿酸血症动物模型研究进展[J].中国药物与临床,2005,5(2)：115—118.
3 Akkasilpa S, Avihingsanon Y, Hanvivadhanakul P, et al. Clinical manifestations of patients with hyperuricemia[J]. J Med Assoc Thai,2004,87(Suppl 2):41-44.
4陈灏珠.实用内科学[M].北京：人民卫生出版社,2005.2602.
5 Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution[J]. J Mol Evol.1992,34(1):78-84.
6梁晓萍,梁琼麟,胡坪,等.高尿酸血症与痛风研究进展[J].中国药理学通报,2008,24(10)：1265-1268.
7 Choi H K, Mount D B, Reginato A M. Pathogenesis of gout [J]. Ann Intern Med,2005, 143(7):499-516.
8薛耀明,李晨钟.痛风的诊断与治疗[M].北京：人民军医出版社,2004.34.
9 Anzai N, Enomoto A, Endou H. Renal urate handling clinical relevance of recent advances [J]. Curr Rheumatol Rep,2005,7(3):227-234.
10Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport [J]. Physiology (Bethesda),2005,20(1):125-133.
11徐立,时乐,赵芳,等.大鼠急性高尿酸血症模型的复制方法初探[J].中国药理学通报,2007,23(7)：976-978.
12陈光亮,徐叔云.高尿酸血症动物模型研究进展[J].中国药理学通报,2004,20(4)：369-373.
13陈颖,李长贵,苗志敏.原发性高尿酸血症发病机制的研究进展[J].国际遗传学杂志,2006,29(1)：59-61.
14 Yamada Y. Complete and partial deficiencies of hypoxanthine guanine phosphoribosyltransferase (HPRT)[J]. Nippon Rinsho,2003,61(Suppl 1):288-293.
15 Mak'BS, Chi CS, Tsai CR, et al. New mutations of the HPRT gene in Lesch-Nyhan syndrome[J]. Pediatr Neurol,2000,23(4):332-335.
16 Jinnah HA, De Gregorio L, Harris JC, et al. The spectrum of inherited mutations causing HPRT deficiency:75 new cases and a review of 196 previously reported cases [J]. Mutat Res,2000,463(3):309-326.
17 Liu SX. The molecular map and detection of HPRT gene mutation[J]. Foreign Medical Sciences-Hygine,2000,27(1):51-56.
18 Duan J, Nilsson L, Lambert B. Structural and functional analysis of mutations at the human hypoxanthine phosphoribosyl transferase (HPRT1) locus [J]. Hum Mutat,2004, 23(6):599-611.
19 Kawasugi K, Takeuchi F. Phosphoribosylpyrophosphate (PRPP) sythetase[J]. Nippon Rinsho,2003,61(Suppl 1):20-23.
20 Garcia-Pavia P, Torres RJ, Rivero M, et al. Phosphoribosylpyrophosphate synthetase. overactivity as a cause of uric acid overproduction in a young woman[J]. Arthritis Rheum,2003,48(7):2036-2041.
21 Fischer H, Esbjornsson M, Sabina R L, et al. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects [J]. J Appl Physiol,2007, 103(1):315-322.
22周莉.痛风的发病机制[J].医学综述,2007,13(21)：1626-1628.
23 Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH trans porter hOATl and its gene structure[J]. Kidney Int,2003,63(1):143-155.
24 Cha SH, Sekine T, Fukushima JI, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney [J]. Mol Pharmacol, 2001,59(5):1277-1286.
25 Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature,2002,417(6887): 447-452.
26 Liu BR, Pritzker K, Ftrestein GS, et al. TLR2 Signaling in chondrocytes drives calcium pyrophesphate dihydrate and monosodium urate crystal-induced nitric oxide gmeration[J]. J Immuol,2005,174(8):5016-5023.
27 Wortmann RL. Recent advances in the management of gout and hyperuricemia[J]. Curr Opin Rheumatol,2005,17(3):319-324.
28 Leal-Pinto E, Cohen BE, Lipkowitz MS, et al. Functional analysis and molecular model of the human urate transporter/channel, hUAT[J]. Am J Physiol Renal Physiol,2002, 283(1):150-163.
29 Lipkowitz MS, Leal-Pinto E, Cohen BE, et al. Galectin 9 is the sugar-regulated urate transporter/channel UAT[J]. Glycoconj J,2004,19(7-9):491-498.
30 Bleasby K, Hall LA, Jennifer JL, et al. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6) [J]. J Pharmacol Exp Ther,2005,314(2):923-931.
31 Erdrnan AR, Mangravte LM, Urban TJ, et al. The human organic anion transporter 3 (OAT3; SLC22A8):genetic variation and functional genomics[J]. Am J Physiol Renal Physiol, 2006,290(4):905-912.
32陈颖,苗志敏,李长贵.原发性高尿酸血症和痛风分子遗传学研究进展[J].国际内分泌代谢杂志,2006,26(3)：184-186.
33 Enomoto A, Niwa T, Kanai Y, et al. Urate transporter and renal hypouricemia[J]. Rinsho Byori,2003,51(9):892-897.
34 Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion[J]. J Am Soc Nephrol,2004,15(1):164-173.
35陆林.浅谈痛风病的药物治疗[J].医学理论与实践,2007,20(6)：651-652.
36陆凤翔,杨云.临床实用药物手册[M].2版.南京：江苏科学技术出版社,2003.123-124.
37 Morris I, Varughese G, Mattingly P. Colchicine in acute gout[J].BMJ,2003,327 (7426): 1275-1276.
38 Matsukawa A, Yoshimura T, Maeda G, et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 receptor antagonist inmonosodium urate crystal-induced rabbit arthritis[J]. Lab Invest,1998,78(5):: 559-569.
39王圣燕,赵晶,车仁宇.痛风的药物治疗研究进展[J].中国医疗前沿,2009,4(9)：42-44.
40 Ben-Chetrit E, Levy M. Colchicine:1998 update [J]. Semin Arthritis Rheum,1998,28(1): 48-59.
41 Lange U, Schuman C, Schmidt KL. Current aspects of colchicine therapy--classical indications and new therapeutic uses[J]. Eur J Med Res,2001,6(4):150-160.
42 Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout:a clinical trial and review of the literature[J]. Semin Arthitis Rheum,1990,19(6):329-336.
43 J Bonnel RA, Villalba ML, Karwoski CB, et al. Deaths associated with inappropriate intravenous colchicines administration[J]. J Emerg Med,2002,22(4):385-387.
44 Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etaricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout:a randomized controlled trial [J]. Arthritis Rheum,2004,50(2):598-606.
45 Pittman JR, Bross MH. Diagnosis and management of gout[J]. Am Fam Physician,1999, 59(7):1799-1806,1810.
46 Sehlesinger N, Hmacher H. Gout:can management be improved? Curr Opin Rheumatol, 2001,3(3):240-244.
47 Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerabillty of rolecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis[J]. Clin Ther,2004,20:399-406.
48陈光亮,王琳琳.防治痛风的药物研究进展[J].国外医学内分泌学分册,2005,25(4)：277-279.
49 Faro AG. Managing problem gout[J]. Ann Acad Med Singapore,1998,27(1):93-99.
50周广宇.抗痛风药的作用机制与分类[J].中国社区医师,2007,16(7)：23-24.
51 Miguelez R, Palacios L, Navarro F, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis[J]. J Lipid Mediat Cell Signal,1996,13(1):35-49.
52尚红,张繁荣,赵东..痛风性关节炎(急性发作)的疼痛治疗[J].中国疼痛医学杂志,2005,11(S)：189-190.
53刘爱苓,杨宝旭.痛风性关节炎的疼痛治疗[J].中国冶金工业医学杂志,2005,22(3)：366-367.
54陈新谦,金有豫,汤光,等.新编药物学[M].15版.北京：人民卫生出版社,2004.205.
55刘波.痛风的病理[J].中国社区医师,2002,16(7)：13-14.
56匿名.主要作用于中枢神经系统的药物[M]／／陈新谦,金有豫.新编药物学[M].14版.北京：人民卫生出版社,1998.163.
57孙琛,杨藻宸.药理学和药物治疗学[M].北京：人民卫生出版社,2000.686.
58张忠辉.痛风与高尿酸血症的进展[J].重庆医学,2007,36(10)：985-988.
59黄火高,韩星海,尚健,等.吡格列酮对大鼠急性痛风性关节炎的防治作用[J].第二军医大学学报,2005,26(12)：1380-1383.
60 Oates JC, Reilly CM, Crosby MB, et al. Peroxisome proliferator-activated receptor gamma agonists:potential use for treating chronic inflammatory diseases [J]. Arthritis Rheum,2002,46(3):598-605.
61 Grau R, Iniguez MA, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Deltal2, 14-prostaglandin J2 in colon carcinoma cells:evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism [J]. Cancer Res,2004,64(15):5162-5171.
62王春辉,李松.黄嘌呤氧化酶抑制剂的研究进展[J].国外医学药学分册,2006,33(5)：351-357.
63同殿元,同正端.现代临床医学指南[M].北京：人民军医出版社,2001.243-244.
64 Unno T, Sugimoto A, Kakuda T. Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa(L.)Pers[J]. J Ethnophamacol,2004,93(2-3):391-395.
65 Nguyen MT, Awale S, Tezuka Y, et al. Xanthine oxidase inhibitors from the heartwood of Vietnamese Caesalpinia sappan[J]. Chem Pham Bull,2005,53(8):984-988.
66 Naito S, Nishimura M. Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes[J]. Yakugaku Zasshi, 2001,121(12):989-994.
67 Naito S, Nishimura M, Tamao Y. Evaluation of the pharmacological actions and pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver[J]. J Pharm Pharmacol,2000,52(2):173-179.
68朱丽臻.痛风的中医药临床研究进展[J].新中医,2007,39(10)：101-102.
69旷惠桃.中医药治疗痛风研究概述[J].湖南中医杂志,2005,21(2)：79-83.
70钱卫东,钱小奇.痛风性关节炎中医药研究进展[J].中华中医药学刊,2008,26(3)：572-573.
71张永生.姜良铎教授治疗痛风经验[J].北京中医药大学学报,2002,25(2)：61-62.
72朱萱萱,陈震,纪伟等.热痹消治疗急性痛风性关节炎的实验研究[J].中国药品标准,2002,3(1)：57-60.
73董雯.痛风病的中医药治疗[J].长春中医药大学学报,2008,24(1)：107-108.
74李涓,易明娟,郭蓉,等.痛风宁口服液治疗急性痛风性关节炎的实验研究[J].华西药学杂志,1998,13(3)：159-162.
75王秀华,张治宇,侯斌,等.清热祛湿法对兔膝关节急性痛风性关节炎细胞因IL-1β和NO的影响[J].中医正骨,2001,13(4)：3-5.
76陈文照,吴士良,姜宏,等.防己黄芪苡汤对急性痛风外周神经递质的影响[J].中国医药学报,1997,12(4)：25-26.
77何永生.鲁贤昌治疗痛风性关节炎的经验[J].中国中医药信息杂志,2004,11(3)：266-267.
78边丽娜,程宇.针灸治疗痛风性关节炎的疗效及机理研究进展[J].针灸临床杂志,2009,25(7)：58-60.
79尚雁君,郭跃伟,黄才国,等.中国南海海绵提取物renierol抗痛风作用的实验研究[J].中国海洋药物杂志,2006,25(5)：25-27.
80宋文冲,王雅芹,陈超.虎参痛风胶囊对高尿酸血症及尿酸性肾病大鼠的影响[J].中国药理学通报,2004,20(3)：342-346.
81刘微,黄晓东,范红艳,等.泽苓痛风饮对高尿酸血症小鼠血尿酸的影响[J].中国民族民间医药,2009,16(23)：59-60.
82王瑾,赵兆琳,王义成.痛风灵Ⅱ号治疗尿酸性肾病合并脂代谢异常的实验研究[J].内蒙古中医药,2008,16(1)：57-58.
83郑蓓.海蜇皮外治痛风1例[J].Journal of External Therapy of TCM,2003,12(4):48-49.
84胡志鹏.壳寡糖的研究进展[J].中国生化药物杂志,2003,24(4)：210-212.
85 Synowiecki J, AI-Khateeb NA. Production, properties,and some new applications of chitin and its derivatives[J]. Crit Rev Food Sci Nutr,2003,43(2):145-171.
86 Romoren K, Thu BJ, Evensen 0, et al. Immersion delivery of plasmid DNA. II.A study of the potentials of a chitosan based delivery system in rainbow trout (Oncorhynchus mykiss) fry[J]. J Control Release,2002,85(1-3):215-225.
87 Risbud M, Bhonde M, Bhonde R. Chitosan-polyvinyl pyrrolidone hydrogel does not activate macrophages potentials for transplantation applications [J]. Cell Transplant,2001,10(2):195-202.
88 Vord PJ, Matthew HW, Silva SP, et al. Evaluation of the biocompatibility of a chatosan scaffol in mice[J]. J Biomed Mater Res,2002,59(3):585-590.
89 Lee SH, Suh JS, Kim HS, et al. Evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-Chitosan complex in patients with rheumatoid arthritis:results at 4-month follow-up [J]. Korean J Radiol,2003,4(3): 170-178.
90 Jie Guan, Xiaoqing Luo, Qi Wang, et al. The inhibitory effects of chitosan oligosaccharide on tumor growth in vivo and in vitro [J]. Chin J Immunol,2007,5(8): 23-25.
91 Zhonghe Wang, Shunjuan Lu, Haisheng Hu, et al. The effects of low-molecular-weight chitooligosaccharides on immune function of patients with cancer by radiotherapy [J]. J Capital Univ (Med Sci),1997,18(1):80-81.
92 Kim HM, Hong SH, Yoo SJ, et al. Differential effects of Chitooligosaccharides on serum cytokine levels in aged subjects[J]. J Med Food,2006,9(3):427-430.
93熊宇龙,匡欣薇,陈卫国,等.壳寡糖的免疫调节效应及其机制研究进展[J].现代生物医学进展,2009,9(9)：1787-1789.
94官杰,罗晓庆,王琪,等.壳寡糖抑制肿瘤作用的实验研究[J].中国免疫学杂志,2007,23(5)：421-425.
95 Zheng Wang, Lanhong Zheng, Shaoli Yang, et al. N-Acetyl chitooligosaceharide is a potent angiogenic inhibitor both in vivo and in vitro [J]. Biochem Biophys Res Commun, 2007,357:26-31.
96吴海明,华晓阳,何登全.壳寡糖抗肿瘤作用及免疫调节机理的研究[J].中华医学研究杂志,2005,5(8)：729-731.
97刘冰,刘万顺,韩宝芹,等.壳寡糖及其衍生物对实验性糖尿病大鼠调节血脂和抗氧化作用[J].山东大学学报(理学版),2006,41(4)：158-163.
98沈若武,王守彪,夏玉军.壳寡糖对新西兰兔骨折愈合的影响[J].解剖学杂志,2005,28(3)：340-342.
99王秀武,杜昱光,白雪芳,等.壳寡糖对肉仔鸡肠道主要菌群、小肠微绒毛密度、免疫功能及生产性能的影响[J].动物营养学报,2003,15(4)：32-35.
100 Yu KH, Ho HH, Chen JY, e.t al. Gout complicated with necrotizing fasciitis report of 15 cases[J]. Rheumatology,2004,13:1-4.
2邵继红,徐耀初,莫宝庆,等.痛风与高尿酸血症的流行病学研究进展[J].疾病控制杂志,2004,8(2)：152-154.
3李昌臣.高尿酸血症的定义及病型分类[J].医师进修杂志,1998,21(6)：281-282.
4赵文婷,姚华.高尿酸血症与相关基因关系的研究[J].泰山医学院学报,2008,29(5)：394-396.
5叶玉津,尹培达.痛风性关节炎的诊治进展[J].新医学,2002,33(9)：524-525.
6 Conaghan PG, Day RO. Risk and benefits of drugs used in the management and prevention of gout[J]. Drugs,1994,11(4):252-258.
7 Ben Chetrit E, Levy M. Colchicine:1998 update [J]. Semin Arthritis Rheum,1998,28(1): 48-59.
8陈光亮,王钦茂,徐叔云.小鼠高尿酸血症模型的研究[J].中国药理学通报,2001,17(3)：350-352.
9陈光亮,张清林,徐叔云,等.酵母致小鼠高尿酸血症模型[J].中国药理学通报,2003,19(4)：4697-4699.
10陈光亮,徐叔云.高尿酸血症动物模型研究进展[J].中国药理学通报,2004,20(4)：369-373.
11陈云凤,肩晓宇,彭介寿.痛风宁I号抗炎及镇痛作用的研究[J].中药药理与临床,2000,16(4)：38-39.
12陈文照,金策,林坚,等.痛风宁对尿酸钠致大鼠关节炎模型前列腺素的影响[J].中国医药学报,2000,15(2)：104-106.
13胡志鹏.壳寡糖的研究进展[J].中国生化药物杂志,2003,24(4)：210-212.
14 Synowiecki J, AI-Khateeb NA. Production, properties, and some new applications of chitin and its derivatives [J]. Crit Rev Food Sci Nutr,2003,43(2):145-171.
15 Romoren K, Thu BJ, Evensen 0. Immersion delivery of plasmid DNA. II. A study of the potentials of a chitosan based delivery system in rainbow trout (Oncorhynchus mykiss) fry[J]. J Control Release,2002,85(1-3):215-225.
16 Risbud M, Bhonde M, Bhonde R. Chitosan-polyvinyl pyrrolidone hydrogel does not activate macrophages potentials for transplantation applications [J]. Cell fransplant,2001,10(2):195-202.
17 Vord PJ, Matthew HW, Silva SP, et al. Evaluation of the biocompatibility of a chatosan scaffol in mice [J]. J Biomed Mater Res,2002,59(3):585-590.
18熊宇龙,匡欣薇,陈卫国,等.壳寡糖的免疫调节效应及其机制研究进展[J].现代生物医学进展,2009,9(9)：1787-1789.
19官杰,罗晓庆,王琪,等.壳寡糖抑制肿瘤作用的实验研究[J].中国免疫学杂志,2007,23(5)：421-425.
20 Zheng Wang, Lanhong Zheng, Shaoli Yang, et al. N-acetylchitooligosaceharide is a potent angiogenic inhibitor both in vivo and in vitro [J]. Biochem Biophys Res Commun, 2007,357(1):26-31.
21吴海明,华晓阳,何登全.壳寡糖抗肿瘤作用及免疫调节机理的研究[J].中华医学研究杂志,2005,5(8)：729-731.
22刘冰,刘万顺,韩宝芹,等.壳寡糖及其衍生物对实验性糖尿病大鼠调节血脂和抗氧化作用[J].山东大学学报(理学版),2006,41(4)：158-163.
23沈若武,王守彪,夏玉军.壳寡糖对新西兰兔骨折愈合的影响[J].解剖学杂志,2005,28(3)：340-342.
24王秀武,杜昱光,白雪芳,等.壳寡糖对肉仔鸡肠道主要菌群、小肠微绒毛密度、免疫功能及生产性能的影响[J].动物营养学报,2003,15(4)：32-35.
25张剑勇,杨卓欣,孙景波,等.护肾痛风泰冲剂对痛风肾大鼠型前胶原的影响[J].中医药学刊,2004,22(2)：245-246.
26王叶新.急性痛风性关节炎的治疗进展[J].中国骨质疏松杂志,2007,13(1)：74-76.
27徐叔云,卞如镰,陈修.药理实验方法学[M].第三版.北京：人民卫生出版社,2002.202-204.
28 Terkeltaub R, Baird S, Sears P, et al. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in air pouch model of acute urate crystal-induced gouty synovitis[J]. Arthritis Rheum,1998, 41(5):900-999.
29 Terkeltaub R. Pathogenesis and treatment of crystal-induced inflammation in Koopman WJ. Arthritis and allied conditions a text book rheumatology [J]. Baltimore Williams and Wilkins,1996,16(5):'2085-2806.
30方圻.现代内科学[M].北京：人民军医出版社,1995.2873-2875.
31 Coderre TJ, Wall PD. Ankle joint urate arthritis (AJUA) in rats:an alternative animal model of arthritis to that produced by Freund's adjuvant[J]. Pain,1987,28(3): 379-393.
32 Coderre TJ, Wall PD. Ankle joint arthritis in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents[J]. Pharm Biochem Behav,1988, 29(3):461-463.
33金红兰,郭瑞新.复方白虎加桂枝汤防治大鼠痛风模型的实验观察[J].深圳中西医结合杂志,2005,15(4)：199-201.
34卢笑倩.痛风急性期的药物治疗与分析[J].哈尔滨医药,2009,29(4)：46.
35 Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation:in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1[J]. Arthritis Rheum,1997, 40(5):955-965.
36刘湘源,李树强.痛风急性发作期的治疗进展[J].中华临床医师杂志,2009,3(3)：474-477.
37甘秀红.痛风病诊治的研究进展[J].右江医学,2007,35(5)：587-589.
38王大山,安利国,杨桂文.壳聚糖对巨噬细胞的双向免疫调节作用[J].生命的化学,2009,29(1)：60-63.
39 Fujiwara K, Ohkawara S, Takagi K, et al. Involvement of CXC chemokine growth-related oncogene-alpha in monosodium urate crystal-induced arthritis in rabbits[J]. Lab Invest,2002,82(10):1297-1304.
40 Matsukawa A, Yoshimura T, Maeda T, et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-lbeta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis[J]. Lab Invest,1998,78(5):559-569.
41 Choi H K, Mount D B, Reginato A M. Pathogenesis of gout[J]. Ann Intern Med,2005, 143(7):499-516.
42张超,曹克光,杨崇青,等.高尿酸血症及尿酸性肾病动物模型的建立及应用[J].实验动物科学与管理,1999,16(4)：18-21.
43苏友新,陈伟宏,王和鸣,等.高尿酸血症及痛风性关节炎的动物模型研究概况[J].中国骨伤,2004,17(7)：444-445.
44王丹,张三印,代勇,等.高尿酸血症及痛风动物模型研究概况[J].山东中医杂志,2008,27(8)：573-575.
45金沈锐,秦旭华.痛风及高尿酸血症动物模型的研究现状和评价[J].中国实验动物学报,2005,13(1)：55-58.
46熊湘明,曲竹秋.大鼠高尿酸血症模型建立[J].天津中医学院学报,2001,20(4)：28-29.
47 Anzai N, Enomoto A, Endou H. Renal urate handling clinical relevance of recent advances [J]. Curr Rheumatol Rep,2005,7(3):227-234.
48 Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport [J]. Physiology (Bethesda),2005,20(1):125-133.
49孔悦,张冰,刘小青,等.黄嘌呤氧化酶活性在高尿酸血症动物模型中的变化[J].北京中医药大学学报,2004,27(6)：38-40.
50朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8)：803-806.
51孟昭亨.痛风[M].第1版.北京：北京医科大学中国协和医科大学联合出版社,1997.285.
52 Meyers OL, Cassim B, Mody GM. Hyperuricemia and gout:clinical guideline 2003[J]. S Afr Med J,2003,93(12):961-971.
53刘波.痛风的病理[J].中国社区医师,2002,16(7)：13-14.
1李昌臣.高尿酸血症的定义及病型分类[J].医师进修杂志,1998,21(6)：281-282.
2林伟青,谢建祥.高尿酸血症动物模型研究进展[J].中国药物与临床,2005,5(2)：115—118.
3 Akkasilpa S, Avihingsanon Y, Hanvivadhanakul P, et al. Clinical manifestations of patients with hyperuricemia[J]. J Med Assoc Thai,2004,87(Suppl 2):41-44.
4陈灏珠.实用内科学[M].北京：人民卫生出版社,2005.2602.
5 Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution[J]. J Mol Evol.1992,34(1):78-84.
6梁晓萍,梁琼麟,胡坪,等.高尿酸血症与痛风研究进展[J].中国药理学通报,2008,24(10)：1265-1268.
7 Choi H K, Mount D B, Reginato A M. Pathogenesis of gout [J]. Ann Intern Med,2005, 143(7):499-516.
8薛耀明,李晨钟.痛风的诊断与治疗[M].北京：人民军医出版社,2004.34.
9 Anzai N, Enomoto A, Endou H. Renal urate handling clinical relevance of recent advances [J]. Curr Rheumatol Rep,2005,7(3):227-234.
10Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport [J]. Physiology (Bethesda),2005,20(1):125-133.
11徐立,时乐,赵芳,等.大鼠急性高尿酸血症模型的复制方法初探[J].中国药理学通报,2007,23(7)：976-978.
12陈光亮,徐叔云.高尿酸血症动物模型研究进展[J].中国药理学通报,2004,20(4)：369-373.
13陈颖,李长贵,苗志敏.原发性高尿酸血症发病机制的研究进展[J].国际遗传学杂志,2006,29(1)：59-61.
14 Yamada Y. Complete and partial deficiencies of hypoxanthine guanine phosphoribosyltransferase (HPRT)[J]. Nippon Rinsho,2003,61(Suppl 1):288-293.
15 Mak'BS, Chi CS, Tsai CR, et al. New mutations of the HPRT gene in Lesch-Nyhan syndrome[J]. Pediatr Neurol,2000,23(4):332-335.
16 Jinnah HA, De Gregorio L, Harris JC, et al. The spectrum of inherited mutations causing HPRT deficiency:75 new cases and a review of 196 previously reported cases [J]. Mutat Res,2000,463(3):309-326.
17 Liu SX. The molecular map and detection of HPRT gene mutation[J]. Foreign Medical Sciences-Hygine,2000,27(1):51-56.
18 Duan J, Nilsson L, Lambert B. Structural and functional analysis of mutations at the human hypoxanthine phosphoribosyl transferase (HPRT1) locus [J]. Hum Mutat,2004, 23(6):599-611.
19 Kawasugi K, Takeuchi F. Phosphoribosylpyrophosphate (PRPP) sythetase[J]. Nippon Rinsho,2003,61(Suppl 1):20-23.
20 Garcia-Pavia P, Torres RJ, Rivero M, et al. Phosphoribosylpyrophosphate synthetase. overactivity as a cause of uric acid overproduction in a young woman[J]. Arthritis Rheum,2003,48(7):2036-2041.
21 Fischer H, Esbjornsson M, Sabina R L, et al. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects [J]. J Appl Physiol,2007, 103(1):315-322.
22周莉.痛风的发病机制[J].医学综述,2007,13(21)：1626-1628.
23 Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH trans porter hOATl and its gene structure[J]. Kidney Int,2003,63(1):143-155.
24 Cha SH, Sekine T, Fukushima JI, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney [J]. Mol Pharmacol, 2001,59(5):1277-1286.
25 Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature,2002,417(6887): 447-452.
26 Liu BR, Pritzker K, Ftrestein GS, et al. TLR2 Signaling in chondrocytes drives calcium pyrophesphate dihydrate and monosodium urate crystal-induced nitric oxide gmeration[J]. J Immuol,2005,174(8):5016-5023.
27 Wortmann RL. Recent advances in the management of gout and hyperuricemia[J]. Curr Opin Rheumatol,2005,17(3):319-324.
28 Leal-Pinto E, Cohen BE, Lipkowitz MS, et al. Functional analysis and molecular model of the human urate transporter/channel, hUAT[J]. Am J Physiol Renal Physiol,2002, 283(1):150-163.
29 Lipkowitz MS, Leal-Pinto E, Cohen BE, et al. Galectin 9 is the sugar-regulated urate transporter/channel UAT[J]. Glycoconj J,2004,19(7-9):491-498.
30 Bleasby K, Hall LA, Jennifer JL, et al. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6) [J]. J Pharmacol Exp Ther,2005,314(2):923-931.
31 Erdrnan AR, Mangravte LM, Urban TJ, et al. The human organic anion transporter 3 (OAT3; SLC22A8):genetic variation and functional genomics[J]. Am J Physiol Renal Physiol, 2006,290(4):905-912.
32陈颖,苗志敏,李长贵.原发性高尿酸血症和痛风分子遗传学研究进展[J].国际内分泌代谢杂志,2006,26(3)：184-186.
33 Enomoto A, Niwa T, Kanai Y, et al. Urate transporter and renal hypouricemia[J]. Rinsho Byori,2003,51(9):892-897.
34 Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion[J]. J Am Soc Nephrol,2004,15(1):164-173.
35陆林.浅谈痛风病的药物治疗[J].医学理论与实践,2007,20(6)：651-652.
36陆凤翔,杨云.临床实用药物手册[M].2版.南京：江苏科学技术出版社,2003.123-124.
37 Morris I, Varughese G, Mattingly P. Colchicine in acute gout[J].BMJ,2003,327 (7426): 1275-1276.
38 Matsukawa A, Yoshimura T, Maeda G, et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 receptor antagonist inmonosodium urate crystal-induced rabbit arthritis[J]. Lab Invest,1998,78(5):: 559-569.
39王圣燕,赵晶,车仁宇.痛风的药物治疗研究进展[J].中国医疗前沿,2009,4(9)：42-44.
40 Ben-Chetrit E, Levy M. Colchicine:1998 update [J]. Semin Arthritis Rheum,1998,28(1): 48-59.
41 Lange U, Schuman C, Schmidt KL. Current aspects of colchicine therapy--classical indications and new therapeutic uses[J]. Eur J Med Res,2001,6(4):150-160.
42 Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout:a clinical trial and review of the literature[J]. Semin Arthitis Rheum,1990,19(6):329-336.
43 J Bonnel RA, Villalba ML, Karwoski CB, et al. Deaths associated with inappropriate intravenous colchicines administration[J]. J Emerg Med,2002,22(4):385-387.
44 Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etaricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout:a randomized controlled trial [J]. Arthritis Rheum,2004,50(2):598-606.
45 Pittman JR, Bross MH. Diagnosis and management of gout[J]. Am Fam Physician,1999, 59(7):1799-1806,1810.
46 Sehlesinger N, Hmacher H. Gout:can management be improved? Curr Opin Rheumatol, 2001,3(3):240-244.
47 Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerabillty of rolecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis[J]. Clin Ther,2004,20:399-406.
48陈光亮,王琳琳.防治痛风的药物研究进展[J].国外医学内分泌学分册,2005,25(4)：277-279.
49 Faro AG. Managing problem gout[J]. Ann Acad Med Singapore,1998,27(1):93-99.
50周广宇.抗痛风药的作用机制与分类[J].中国社区医师,2007,16(7)：23-24.
51 Miguelez R, Palacios L, Navarro F, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis[J]. J Lipid Mediat Cell Signal,1996,13(1):35-49.
52尚红,张繁荣,赵东..痛风性关节炎(急性发作)的疼痛治疗[J].中国疼痛医学杂志,2005,11(S)：189-190.
53刘爱苓,杨宝旭.痛风性关节炎的疼痛治疗[J].中国冶金工业医学杂志,2005,22(3)：366-367.
54陈新谦,金有豫,汤光,等.新编药物学[M].15版.北京：人民卫生出版社,2004.205.
55刘波.痛风的病理[J].中国社区医师,2002,16(7)：13-14.
56匿名.主要作用于中枢神经系统的药物[M]／／陈新谦,金有豫.新编药物学[M].14版.北京：人民卫生出版社,1998.163.
57孙琛,杨藻宸.药理学和药物治疗学[M].北京：人民卫生出版社,2000.686.
58张忠辉.痛风与高尿酸血症的进展[J].重庆医学,2007,36(10)：985-988.
59黄火高,韩星海,尚健,等.吡格列酮对大鼠急性痛风性关节炎的防治作用[J].第二军医大学学报,2005,26(12)：1380-1383.
60 Oates JC, Reilly CM, Crosby MB, et al. Peroxisome proliferator-activated receptor gamma agonists:potential use for treating chronic inflammatory diseases [J]. Arthritis Rheum,2002,46(3):598-605.
61 Grau R, Iniguez MA, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Deltal2, 14-prostaglandin J2 in colon carcinoma cells:evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism [J]. Cancer Res,2004,64(15):5162-5171.
62王春辉,李松.黄嘌呤氧化酶抑制剂的研究进展[J].国外医学药学分册,2006,33(5)：351-357.
63同殿元,同正端.现代临床医学指南[M].北京：人民军医出版社,2001.243-244.
64 Unno T, Sugimoto A, Kakuda T. Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa(L.)Pers[J]. J Ethnophamacol,2004,93(2-3):391-395.
65 Nguyen MT, Awale S, Tezuka Y, et al. Xanthine oxidase inhibitors from the heartwood of Vietnamese Caesalpinia sappan[J]. Chem Pham Bull,2005,53(8):984-988.
66 Naito S, Nishimura M. Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes[J]. Yakugaku Zasshi, 2001,121(12):989-994.
67 Naito S, Nishimura M, Tamao Y. Evaluation of the pharmacological actions and pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver[J]. J Pharm Pharmacol,2000,52(2):173-179.
68朱丽臻.痛风的中医药临床研究进展[J].新中医,2007,39(10)：101-102.
69旷惠桃.中医药治疗痛风研究概述[J].湖南中医杂志,2005,21(2)：79-83.
70钱卫东,钱小奇.痛风性关节炎中医药研究进展[J].中华中医药学刊,2008,26(3)：572-573.
71张永生.姜良铎教授治疗痛风经验[J].北京中医药大学学报,2002,25(2)：61-62.
72朱萱萱,陈震,纪伟等.热痹消治疗急性痛风性关节炎的实验研究[J].中国药品标准,2002,3(1)：57-60.
73董雯.痛风病的中医药治疗[J].长春中医药大学学报,2008,24(1)：107-108.
74李涓,易明娟,郭蓉,等.痛风宁口服液治疗急性痛风性关节炎的实验研究[J].华西药学杂志,1998,13(3)：159-162.
75王秀华,张治宇,侯斌,等.清热祛湿法对兔膝关节急性痛风性关节炎细胞因IL-1β和NO的影响[J].中医正骨,2001,13(4)：3-5.
76陈文照,吴士良,姜宏,等.防己黄芪苡汤对急性痛风外周神经递质的影响[J].中国医药学报,1997,12(4)：25-26.
77何永生.鲁贤昌治疗痛风性关节炎的经验[J].中国中医药信息杂志,2004,11(3)：266-267.
78边丽娜,程宇.针灸治疗痛风性关节炎的疗效及机理研究进展[J].针灸临床杂志,2009,25(7)：58-60.
79尚雁君,郭跃伟,黄才国,等.中国南海海绵提取物renierol抗痛风作用的实验研究[J].中国海洋药物杂志,2006,25(5)：25-27.
80宋文冲,王雅芹,陈超.虎参痛风胶囊对高尿酸血症及尿酸性肾病大鼠的影响[J].中国药理学通报,2004,20(3)：342-346.
81刘微,黄晓东,范红艳,等.泽苓痛风饮对高尿酸血症小鼠血尿酸的影响[J].中国民族民间医药,2009,16(23)：59-60.
82王瑾,赵兆琳,王义成.痛风灵Ⅱ号治疗尿酸性肾病合并脂代谢异常的实验研究[J].内蒙古中医药,2008,16(1)：57-58.
83郑蓓.海蜇皮外治痛风1例[J].Journal of External Therapy of TCM,2003,12(4):48-49.
84胡志鹏.壳寡糖的研究进展[J].中国生化药物杂志,2003,24(4)：210-212.
85 Synowiecki J, AI-Khateeb NA. Production, properties,and some new applications of chitin and its derivatives[J]. Crit Rev Food Sci Nutr,2003,43(2):145-171.
86 Romoren K, Thu BJ, Evensen 0, et al. Immersion delivery of plasmid DNA. II.A study of the potentials of a chitosan based delivery system in rainbow trout (Oncorhynchus mykiss) fry[J]. J Control Release,2002,85(1-3):215-225.
87 Risbud M, Bhonde M, Bhonde R. Chitosan-polyvinyl pyrrolidone hydrogel does not activate macrophages potentials for transplantation applications [J]. Cell Transplant,2001,10(2):195-202.
88 Vord PJ, Matthew HW, Silva SP, et al. Evaluation of the biocompatibility of a chatosan scaffol in mice[J]. J Biomed Mater Res,2002,59(3):585-590.
89 Lee SH, Suh JS, Kim HS, et al. Evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-Chitosan complex in patients with rheumatoid arthritis:results at 4-month follow-up [J]. Korean J Radiol,2003,4(3): 170-178.
90 Jie Guan, Xiaoqing Luo, Qi Wang, et al. The inhibitory effects of chitosan oligosaccharide on tumor growth in vivo and in vitro [J]. Chin J Immunol,2007,5(8): 23-25.
91 Zhonghe Wang, Shunjuan Lu, Haisheng Hu, et al. The effects of low-molecular-weight chitooligosaccharides on immune function of patients with cancer by radiotherapy [J]. J Capital Univ (Med Sci),1997,18(1):80-81.
92 Kim HM, Hong SH, Yoo SJ, et al. Differential effects of Chitooligosaccharides on serum cytokine levels in aged subjects[J]. J Med Food,2006,9(3):427-430.
93熊宇龙,匡欣薇,陈卫国,等.壳寡糖的免疫调节效应及其机制研究进展[J].现代生物医学进展,2009,9(9)：1787-1789.
94官杰,罗晓庆,王琪,等.壳寡糖抑制肿瘤作用的实验研究[J].中国免疫学杂志,2007,23(5)：421-425.
95 Zheng Wang, Lanhong Zheng, Shaoli Yang, et al. N-Acetyl chitooligosaceharide is a potent angiogenic inhibitor both in vivo and in vitro [J]. Biochem Biophys Res Commun, 2007,357:26-31.
96吴海明,华晓阳,何登全.壳寡糖抗肿瘤作用及免疫调节机理的研究[J].中华医学研究杂志,2005,5(8)：729-731.
97刘冰,刘万顺,韩宝芹,等.壳寡糖及其衍生物对实验性糖尿病大鼠调节血脂和抗氧化作用[J].山东大学学报(理学版),2006,41(4)：158-163.
98沈若武,王守彪,夏玉军.壳寡糖对新西兰兔骨折愈合的影响[J].解剖学杂志,2005,28(3)：340-342.
99王秀武,杜昱光,白雪芳,等.壳寡糖对肉仔鸡肠道主要菌群、小肠微绒毛密度、免疫功能及生产性能的影响[J].动物营养学报,2003,15(4)：32-35.
100 Yu KH, Ho HH, Chen JY, e.t al. Gout complicated with necrotizing fasciitis report of 15 cases[J]. Rheumatology,2004,13:1-4.